Growth momentum Reference Medicine operates in the oncology biospecimen space with a revenue range of 10M-25M and a small, agile team (11-50 employees). This combination suggests a scalable partner for biopharma and diagnostic developers seeking reliable, fast access to annotated tumor samples, cfDNA with known variants, and NGS-ready material.

Expanded offerings The company provides a broad catalog of biospecimens (FFPE tissue, fresh/frozen, matched sets, clinical remnant material) and emphasizes turnkey procurement convenience, presenting cross-selling opportunities to CROs and diagnostic developers requiring end-to-end sample sourcing alongside their existing services.

Recognition leverage Recent accolades and finalist status in EY Entrepreneur of the Year and Small Business Awards, plus Best Places to Work recognition, offer credibility to engage enterprise clients and risk-averse biopharma partners seeking proven, high-trust suppliers.

Strategic partnerships Active participation in industry events and a focus on oncology diagnostics and therapeutics positioning suggest openings for co-development pilots, strategic collaborations, or preferred supplier arrangements with larger biopharma and diagnostic players seeking specialized biospecimen sourcing.

Technology enablement A tech stack featuring Google Ads, iCIMS, Calendly, AWS, and Webflow indicates a modern, outbound-friendly sales motion and scalable operations; leverage digital channels and streamlined onboarding to accelerate client acquisition and improve sample-order turnaround.